Open Label, Multicenter, Real World Practice of Durvalumab in Lung Cancer (Imfinzi PMS) - Imfinzi PMS

The objectives of this study are to assess safety and efficacy of Imfinzi (durvalumab) in a real world setting in patients with non-small cell lung cancer (NSCLC) or SCLC treated with Imfinzi under the approved indication in Korea.

Primary objective : To assess safety of Imfinzi for patients with NSCLC or SCLC treated with Imfinzi under the approved indication in Korea Outcome Measure: − Safety (adverse event (AE), serious adverse events (SAE), adverse drug reaction (ADR), serious adverse drug reaction (SADR), adverse events of special interest (AESI), adverse events leading to discontinuation (DAE), and adverse events leading to deaths (fatal AE)) − Dose interruptions − Duration of treatment − Reason for treatment discontinuation Secondary objective: To assess efficacy of Imfinzi for patients with NSCLC or SCLC treated with Imfinzi under the approved indication in Korea Outcome Measure: − Progression free survival (PFS) − Objective response rate (ORR) − Duration of response (DoR)